|

PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation

RECRUITINGSponsored by University Hospital, Lille
Actively Recruiting
SponsorUniversity Hospital, Lille
Started2023-02-16
Est. completion2031-02
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05009797

Summary

Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood. The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a prospective cohort of 750 patients undergoing atrial fibrillation catheter ablation. The secondary aims are to assess the incidence of major adverse cardiovascular outcomes (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patient undergoing atrial fibrillation catheter ablation
* Able to give their consent

Exclusion Criteria:

* Childs
* Patient under guardianship
* Patients unable to give their consent
* Pregnancy

Conditions2

Atrial FibrillationHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.